Literature DB >> 1993358

Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation.

S Piddlesden1, H Lassmann, I Laffafian, B P Morgan, C Linington.   

Abstract

The effects of decomplementation by cobra venom factor (CVF) on the pathogenesis of inflammation and demyelination in experimental allergic encephalomyelitis (EAE) and acute antibody-mediated demyelinating EAE (ADEAE) have been quantified histologically and immunocytochemically. In rats immunized with 50 micrograms of myelin basic protein in Freund's complete adjuvant containing 100 micrograms heat-killed Mycobacterium tuberculosis H37Ra, clinical signs of EAE were completely suppressed by two injections of CVF given 9 and 12 days post-immunization. Suppression of clinical disease was associated with a dramatic reduction in peri-vascular inflammation in the CNS, although immunohistochemical staining identified small numbers of infiltrating T cells and macrophages. In contrast, CVF treatment had no significant effect on the clinical severity of ADEAE and although C9 deposition within the CNS was virtually abolished, there was no statistically significant decrease in the extent of demyelination or inflammation. These observations indicate that in the absence of complement components C3 and C5 an antibody-dependent cell-mediated cytotoxic response plays an important role in the pathogenesis of antibody-mediated demyelination. The major role of the complement cascade in EAE appears to be the generation of pro-inflammatory factors that enhance the inflammatory response within the CNS in animals facing a mild encephalitogenic challenge.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993358      PMCID: PMC1535261          DOI: 10.1111/j.1365-2249.1991.tb05622.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes.

Authors:  A F Williams; G Galfrè; C Milstein
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

2.  Prevention of experimental allergic encephalomyelitis with cobra venom factor.

Authors:  H Pabst; N K Day; H Gewurz; R A Good
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

3.  Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis.

Authors:  L G Epstein; J W Prineas; C S Raine
Journal:  J Neurol Sci       Date:  1983 Oct-Nov       Impact factor: 3.181

4.  Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs.

Authors:  M A Morariu; A P Dalmasso
Journal:  Ann Neurol       Date:  1978-11       Impact factor: 10.422

5.  A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody.

Authors:  C Linnington; M Webb; P L Woodhams
Journal:  J Neuroimmunol       Date:  1984 Sep-Oct       Impact factor: 3.478

6.  Myelin basic proteins.

Authors:  E H Eylar; P J Kniskern; J J Jackson
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

7.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Studies on demyelination in vitro: the requirement of membrane attack components of the complement system.

Authors:  W T Liu; P Vanguri; M L Shin
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  Purification of C8 and C9 from rat serum.

Authors:  J Jones; I Laffafian; B P Morgan
Journal:  Complement Inflamm       Date:  1990

10.  Cellular events in the induction of experimental allergic encephalomyelitis in rats.

Authors:  L Ortiz-Ortiz; W O Weigle
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  18 in total

1.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement.

Authors:  S J Piddlesden; H Lassmann; F Zimprich; B P Morgan; C Linington
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 2.  Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.

Authors:  Monica K Mann; Avijit Ray; Sreemanti Basu; Christopher L Karp; Bonnie N Dittel
Journal:  Autoimmunity       Date:  2012-04-19       Impact factor: 2.815

3.  Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

Authors:  Brigid K Jensen; Hubert Monnerie; Maggie V Mannell; Patrick J Gannon; Cagla Akay Espinoza; Michelle A Erickson; Annadora J Bruce-Keller; Benjamin B Gelman; Lisa A Briand; R Christopher Pierce; Kelly L Jordan-Sciutto; Judith B Grinspan
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

4.  Delayed myelination in an intrauterine growth retardation model is mediated by oxidative stress upregulating bone morphogenetic protein 4.

Authors:  Mary V Reid; Kaitlin A Murray; Eric D Marsh; Jeffrey A Golden; Rebecca A Simmons; Judith B Grinspan
Journal:  J Neuropathol Exp Neurol       Date:  2012-07       Impact factor: 3.685

5.  Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

Authors:  C P Genain; M H Nguyen; N L Letvin; R Pearl; R L Davis; M Adelman; M B Lees; C Linington; S L Hauser
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors.

Authors:  Eduard Urich; Ilona Gutcher; Marco Prinz; Burkhard Becher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-22       Impact factor: 11.205

7.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

Review 9.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

10.  Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  I Huitinga; S R Ruuls; S Jung; N Van Rooijen; H P Hartung; C D Dijkstra
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.